Published in
Elsevier, Lung Cancer, (108), p. 154-160
DOI: 10.1016/j.lungcan.2017.03.009
Links
Tools
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib
Journal article published in 2017 by
Teresa Moran,
Ramón Palmero,
Mariano Provencio 
,
Amelia Insa ,
Margarita Majem,
Noemí Reguart,
Joaquim Bosch-Barrera,
Dolores Isla ,
Enric Carcereny Costa,
Chooi Lee,
Marta Puig,
Sandrine Kraemer,
David Schnell,
Rafael Rosell
,
Amelia Insa ,
Margarita Majem,
Noemí Reguart,
Joaquim Bosch-Barrera,
Dolores Isla ,
Enric Carcereny Costa,
Chooi Lee,
Marta Puig,
Sandrine Kraemer,
David Schnell,
Rafael Rosell
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 